Alan Lichtenstein

Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein

Elizabeta Nemeth, Erika V. Valore, Mary Territo et al. · Blood · 2003 · 1.4K citations · Full text

Medicine, Hematology, Immunology +14

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

James R. Berenson, Alan Lichtenstein, Lester Porter et al. · New England Journal of Medicine · 1996 · 1.1K citations

Medicine, Oncology, Pharmacotherapy +16

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.

James R. Berenson, Alan Lichtenstein, Lisa A. Porter et al. · Journal of Clinical Oncology · 1998 · 653 citations

Medicine, Pharmacology, Pharmacotherapy +14

Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade

Yijiang Shi, Huajun Yan, Patrick Frost et al. · Molecular Cancer Therapeutics · 2005 · 370 citations · Full text

Medicine, Cancer Biology, Pharmacology +14

Apoptotic vs. Nonapoptotic Cytotoxicity Induced by Hydrogen Peroxide

Agnes Gardner, Fenghao Xu, Catherine Fady et al. · Free Radical Biology and Medicine · 1997 · 359 citations

Life Sciences, Cell Biology, Toxicology +14